Efficacy and Safety of Drugs Used for Dyslipidemia

Main Article Content

Siraprapa Tubtim

Article Details

How to Cite
Tubtim S. Efficacy and Safety of Drugs Used for Dyslipidemia. Thai Food and Drug J [Internet]. 2020 Sep. 9 [cited 2024 Jun. 20];27(3):4-12. Available from: https://he01.tci-thaijo.org/index.php/fdajournal/article/view/244944
Review Article


1. Talbert RL. Dyslipidemia. In: Dipiro JT,Talbert RL, Yee GC, Matzke GR, Wells BG,Michael Posey L, editors. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. USA:

2. Wiggins BS, Morris PB. Dyslipidemia, Atherosclerosis and Coronary Heart Disease.In: Zeind CS, Carvalho MG, editors. Applied Therapeutics: The Clinical Use of Drugs. 11th ed.China: Wolters Kluwer;2018. p.100-31.

3. Sattar N, Preiss D, Murray HM, et al. Statin and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010;375:735-42.

4. Ko MJ, Jo AJ, Kim YJ, et al. Time-and dosedependent association of statin use with risk of clinically relevant new-onset diabetes mellitus in primary prevention: A nationwide
observational cohort study. J Am Heart Assoc 2019;8:e011320.

5. Richardson K, Schoen M, French B, et al.Statins and cognitive function: A systematic review. Ann Intern Med 2013;159:688-97.

6. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97.

7. Bach RG, Cannon CP, Giugliano RP, et al.Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndromes among patients 75 years
or older: A secondary analysis of a randomized clinical trial. JAMA Cardiol 2019; 4(9):846-54.

8. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N Engl J Med 2011;365: 2255-67.

9. Landray MJ, Haynes R, Hopewell JC, et al. Effect of extended-release niacin with laropiprant in high risk patients. N Engl J Med 2014; 371:203-12.

10. Cuchel M, Meagher EA, Du Toit Theron H,et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in homozygous familial hypercholesterolemia:
A single-arm, open-label phase 3 study.Lancet 2013;381(9860): 40-6.

11. Blom DJ, Averna M, Meagher E, et al. Longterm efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide
in patients with homozygous familial hypercholesterolemia. Circulation 2017; 136:332-5.

12. Harada-Shiba M, Ikewaki K, Nohara A, et al.Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercho lesterolemia. J Atheroscler Thromb 2017;24:402-11.

13. Nohara A, Otsubo Y, Yanagi K, et al. Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): Result from the AEGR-733-301 Longterm extension trial. J Atheroscler Thromb 2019;26:368-77.

14. Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019; 380: 1022-32.

15. Goldberg AC, Leiter LA, Stores EG, et al.Effect of bempedoic acid VS placebo added to maximally tolerated Statins on low-density lipoprotein cholesterol in patients at high
risk for cardiovascular disease: The Clear Wisdom Randomized Clinical Trial. JAMA 2019; 322(18):1780-8.

16. Hu Y, Hu FB, Manson JE, et al. Marine omega-3 supplementation and cardiovascular disease. An updated meta-analysis of 13 randomized controlled trials involving
127,477 participants. J Am Heart Assoc 2019;

17. Sabatine MS, Giugliano RP, Keech AC, et al.Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22.

18. Fogacci F, Ferri N, Toth PP, et al. Efficacy and safety of mipomersen: A systematic review and meta-analysis of randomized clinical trials. Drugs 2019;79:751-66.

19. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382(16):1507-19.